Cancer Genetics and Epigenetics, 2025, Vol.13, No.3, 136-144 http://medscipublisher.com/index.php/cge 144 Lee J., Veena M., Choi Y., Shin D., and Khan S., 2025, Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors, Frontiers in Immunology, 15: 1489827. https://doi.org/10.3389/fimmu.2024.1489827 Lu J., and Jiang G., 2022, The journey of CAR-T therapy in hematological malignancies, Molecular Cancer, 21(1): 194. https://doi.org/10.1186/s12943-022-01663-0 Lin H.L., Cheng J., Mu W., Zhou J., and Zhu L., 2021, Advances in universal CAR-T cell therapy, Frontiers in Immunology, 12: 744823. https://doi.org/10.3389/fimmu.2021.744823 Larson R.C., and Maus M.V., 2021, Recent advances and discoveries in the mechanisms and functions of CAR T cells, Nature Reviews Cancer, 21(3): 145-161 https://doi.org/10.1038/s41568-020-00323-z Ma J.C., Li P.C., Sun W.Y., and Li C.B., 2024, The role of circulating tumor cells in non-invasive colon cancer diagnosis, Cancer Genetics and Epigenetics, 12(5): 254-269. https://doi.org/10.5376/cge.2024.12.0025 Merhi M., Cherif H., Inchakalody V., Maccalli C., Steinhoff M., Alam M., Uddin S., Dermime S., Maalej K., Marincola F., and Mestiri S., 2023, CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances, Molecular Cancer, 22(1): 20. https://doi.org/10.1186/s12943-023-01723-z Roex G., Flumens D., Luo F., Anguille S., Wouters K., Lion E., Timmers M., Chu Y., Campillo-Davo D., Berneman Z., and Schroyens W., 2020, Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma, Journal of Hematology and Oncology, 13(1): 164. https://doi.org/10.1186/s13045-020-01001-1 Sterner R.C., and Sterner R.M., 2021, CAR-T cell therapy: current limitations and potential strategies, Blood Cancer Journal, 11(4): 69. https://doi.org/10.1038/s41408-021-00459-7 Wang C.,Wang J., Che S., and Zhao H., 2023, CAR-T cell therapy for hematological malignancies: history, status and promise, Heliyon, 9(11): e21776. https://doi.org/10.1016/j.heliyon.2023.e21776 Wang Z., Li P., Zeng X., Guo J., Zhang C., Fan Z., Wang Z., Zhu P., and Chen Z., 2025, CAR-T therapy dilemma and innovative design strategies for next generation, Cell Death and Disease, 16(1): 211. https://doi.org/10.1038/s41419-025-07454-x Xiang X., He Q., Ou Y., Wu Y., and Wang W., 2020, Efficacy and safety of CAR-Modified T cell therapy in patients with relapsed or refractory multiple myeloma: a meta-analysis of prospective clinical trials, Frontiers in Pharmacology, 11: 544754. https://doi.org/10.3389/fphar.2020.544754 Zhou D., Zhu X., and Xiao Y., 2024, CAR-T cell combination therapies in hematologic malignancies, Experimental Hematology and Oncology, 13(1): 69. https://doi.org/10.1186/s40164-024-00536-0 Yu W., and Hua Z., 2019, Chimeric antigen receptor T-cell (CAR T) therapy for hematologic and solid malignancies: efficacy and safety-a systematic review with meta-analysis, Cancers, 11(1): 47. https://doi.org/10.3390/cancers11010047 Zhang M., Tian Y., Wang Q., Huang H., Qi Y., Zhang J., Li D., Yang J., Zhao K., Tan B., Du B., Chen A., Wang D., Wei G., Cui J., Zhang L., Wu Y., Li W., Liu M., Li D., Li Y., and Hu Y., 2022, Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL, Nature, 609: 369-374. https://doi.org/10.1038/s41586-022-05140-y Zheng Z., Bei J., Su T., Dong J., Shao L., Jin Y., Wu J., and Chen S., 2025, In-depth analysis of the safety of CAR-T cell therapy for solid tumors, Frontiers in Immunology, 16: 1548979. https://doi.org/10.3389/fimmu.2025.1548979 Zhou J., Milone M., Melenhorst J., Chen S., Xu J., Collins M., and Powell D., 2021, Engineering enhanced CAR T-cells for improved cancer therapy, Nature Cancer, 2: 780-793. https://doi.org/10.1038/s43018-021-00241-5
RkJQdWJsaXNoZXIy MjQ4ODYzNA==